Showing results (161-170 of 174) with videos related to
Sort By:
Pageof 18
Journal of Veterinary Pharmacology and Therapeutics|May 22, 2023
The effect of doxapram on survival and APGAR score in newborn puppies delivered by elective caesarean: A randomized controlled trialTimothy H Hyndman, Shelby Fretwell, Ross S Bowden, et al.Journal of Medicinal Chemistry|January 15, 2016
Robenidine Analogues as Gram-Positive Antibacterial AgentsRebecca J Abraham, Andrew J Stevens, Kelly A Young, et al.Frontiers in Microbiology|August 28, 2020
In vitro Activity of Robenidine Analog NCL195 in Combination With Outer Membrane Permeabilizers Against Gram-Negative Bacterial Pathogens and Impact on Systemic Gram-Positive Bacterial Infection in MiceHongfei Pi, Hang Thi Nguyen, Henrietta Venter, et al.Plos One|July 17, 2018
Bioluminescent murine models of bacterial sepsis and scald wound infections for antimicrobial efficacy testingAbiodun D Ogunniyi, Zlatko Kopecki, Elizabeth E Hickey, et al.Microbiology Spectrum|April 30, 2026
In vitro activity of robenidine analogue NCL195 against methicillin-resistant Staphylococcus pseudintermediusSayara Bista, Hang Thi Nguyen, Tatiana P Soares da Costa, et al.Bioorganic & Medicinal Chemistry Letters|December 17, 2009
Synthesis and evaluation of 3-amino-6-aryl-pyridazines as selective CB(2) agonists for the treatment of inflammatory painRobert J Gleave, Paul J Beswick, Andrew J Brown, et al.Plos One|September 6, 2017
Evaluation of robenidine analog NCL195 as a novel broad-spectrum antibacterial agentAbiodun D Ogunniyi, Manouchehr Khazandi, Andrew J Stevens, et al.Journal of Medicinal Chemistry|December 10, 2016
Fragment-Based Approach to the Development of an Orally Bioavailable Lactam Inhibitor of Lipoprotein-Associated Phospholipase A2 (Lp-PLA2)Alison J-A Woolford, Philip J Day, Véronique Bénéton, et al.ACS Medicinal Chemistry Letters|July 21, 2015
Fragment-Based Discovery of Potent and Selective DDR1/2 InhibitorsChristopher W Murray, Valerio Berdini, Ildiko M Buck, et al.Journal of Medicinal Chemistry|August 10, 2018
A Fragment-Derived Clinical Candidate for Antagonism of X-Linked and Cellular Inhibitor of Apoptosis Proteins: 1-(6-[(4-Fluorophenyl)methyl]-5-(hydroxymethyl)-3,3-dimethyl-1 H,2 H,3 H-pyrrolo[3,2- b]pyridin-1-yl)-2-[(2 R,5 R)-5-methyl-2-([(3R)-3-methylmorpholin-4-yl]methyl)piperazin-1-yl]ethan-1-one (ASTX660)Christopher N Johnson, Jong Sook Ahn, Ildiko M Buck, et al.Pageof 18